TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17548693

Group type: EXPERIMENTAL
Intervention: Serum alpha‐tocopherol supplementation (50 mg daily for 5‐8 years)
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: Higher serum alpha‐tocopherol
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: Supplementation with either alpha‐tocopherol or beta‐carotene
Number of subjects: 29133

Group type: COMPARATOR
Intervention: Dietary tocopherols and tocotrienols
Number of subjects: 29133
Study: 15233282

Group type: EXPERIMENTAL
Intervention: Disopyramide (6 mg/kg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Mexiletine (4 mg/kg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pilsicainide (4 mg/kg)
Number of subjects: 35
Study: 11407971

Group type: EXPERIMENTAL
Intervention: Topically applied vitamin C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9203234

Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose at endpoint: 5.9 mg/day)
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 945
Study: 11767424

Group type: EXPERIMENTAL
Intervention: 10 ml of physiological saline injection (Group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No injection (Group B)
Number of subjects: 70
Study: 2888795

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Celiprolol and Metoprolol
Number of subjects: 20
Study: 31959341

Group type: EXPERIMENTAL
Intervention: FOLFOX4-bevacizumab
Number of subjects: 2867

Group type: EXPERIMENTAL
Intervention: XELOX-bevacizumab
Number of subjects: 2867

Group type: COMPARATOR
Intervention: FOLFOX4
Number of subjects: 2867
Study: 29443425

Group type: COMPARATOR
Intervention: Low AAC (AAC24 score 0 or 1)
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Moderate AAC (AAC24 score 2-5)
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: High AAC (AAC24 score ≥6)
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: High AAC
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Moderate AAC
Number of subjects: 1052
Study: 27184606

Group type: EXPERIMENTAL
Intervention: Ex-PRESS implantation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 64
Study: 25322078

Group type: EXPERIMENTAL
Intervention: COPD breathlessness manual (CM)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Information booklets (IB)
Number of subjects: 222
Study: 24365207

Group type: EXPERIMENTAL
Intervention: nCPAP (nasal CPAP)
Number of subjects: 73

Group type: COMPARATOR
Intervention: FmCPAP (full face mask CPAP)
Number of subjects: 73
Study: 20570240

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 0.02% MMC 1 month before bare scleral excision
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conjunctival rotational flap with intraoperative 0.02% MMC for 2 minutes
Number of subjects: 82
Study: 18812325

Group type: EXPERIMENTAL
Intervention: Isoflavone supplement (80 mg/day)
Number of subjects: 102
Study: 16911386

Group type: EXPERIMENTAL
Intervention: 1% topical methotrexate gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (vaseline ointment)
Number of subjects: 40
Study: 12816908

Group type: EXPERIMENTAL
Intervention: 0.39 mg THC/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 0.47 mg THC/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 7.5 mg THC/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 14.8 mg THC/day
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (0 mg THC/day)
Number of subjects: 7
Study: 11053334

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Theophylline (4.5 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg) and Theophylline (4.5 mg/kg)
Number of subjects: 15
Study: 8730405

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 23
Study: 1428268

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-amiodarone
Number of subjects: 24
Study: 6381186

Group type: EXPERIMENTAL
Intervention: 4-amino-salicylic acid (4-ASA) enemas (1 g)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 4-amino-salicylic acid (4-ASA) enemas (2 g)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo enemas
Number of subjects: 52
Study: 31390900

Group type: EXPERIMENTAL
Intervention: Stress management program (weekly group-based sessions over an 8-week period)
Number of subjects: 55
Study: 30009632

Group type: EXPERIMENTAL
Intervention: AF-CBT
Number of subjects: 195

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 195
Study: 26556894

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 25

Group type: COMPARATOR
Intervention: Calisthenics-and-breathing exercises
Number of subjects: 25
Study: 25459920

Group type: EXPERIMENTAL
Intervention: Case management intervention (home visits by case managers at least once a month)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (no case management intervention)
Number of subjects: 153
Study: 22656396

Group type: EXPERIMENTAL
Intervention: Modified Reach Out and Read (ROR) program, receiving anticipatory guidance and an appropriate children's book at a well-baby clinic.
Number of subjects: 415

Group type: COMPARATOR
Intervention: Control group receiving standard pediatric outpatient service.
Number of subjects: 415
Study: 21510527

Group type: EXPERIMENTAL
Intervention: Injection clonidine 150 mcg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Injection midazolam 5 mg
Number of subjects: 60
Study: 18633172

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nifedipine 20 mg
Number of subjects: 40
Study: 15711112

Group type: EXPERIMENTAL
Intervention: Combined epidural and general anesthesia (CEGA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 50
Study: 11919123

Group type: EXPERIMENTAL
Intervention: Women with type 1 diabetes
Number of subjects: 120

Group type: COMPARATOR
Intervention: Age-matched control group of healthy women
Number of subjects: 120
Study: 9989964

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 415

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study: 7482266

Group type: EXPERIMENTAL
Intervention: Thrombolysis (urokinase)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Surgical intervention
Number of subjects: 114
Study: 2246712

Group type: EXPERIMENTAL
Intervention: HCl supplementation (0.01-0.02 ml of 1 N HCl/ml of milk)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Water supplementation (control)
Number of subjects: 68
Study: 6352793

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous treatment
Number of subjects: 7

Group type: COMPARATOR
Intervention: Traditional intensive insulin therapy
Number of subjects: 7
Study: 31248268

Group type: EXPERIMENTAL
Intervention: Statin therapy (new users)
Number of subjects: 8018

Group type: COMPARATOR
Intervention: Nonusers of statins (control group)
Number of subjects: 8018
Study: 30630808

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 200
Study: 27042828

Group type: EXPERIMENTAL
Intervention: Highest tertile of sodium intake in women
Number of subjects: 1805

Group type: EXPERIMENTAL
Intervention: Highest quartile of UA and tertile of sodium intake
Number of subjects: 1805

Group type: EXPERIMENTAL
Intervention: Highest tertile of sodium intake in men
Number of subjects: 1805
Study: 24269085

Group type: EXPERIMENTAL
Intervention: High IOP (22 to 40 mm Hg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal IOP (10 to 21 mm Hg)
Number of subjects: 0
Study: 23129559

Group type: EXPERIMENTAL
Intervention: Mindfulness‐based Art Therapy (MBAT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Education control group
Number of subjects: 18
Study: 20558922

Group type: EXPERIMENTAL
Intervention: Miglitol 75 mg per meal
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg per meal
Number of subjects: 22
Study: 18259090

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 80 mg propranolol (Inderal)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: aspirin + propranolol
Number of subjects: 73

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 73
Study: 16973686

Group type: EXPERIMENTAL
Intervention: Strict rate control (AFFIRM) aiming for resting heart rate <=80 bpm and heart rate during daily activity <=110 bpm
Number of subjects: 1091

Group type: COMPARATOR
Intervention: Lenient rate control (RACE) aiming for resting heart rate <100 bpm
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Patients with mean heart rates during AF within the AFFIRM criteria (<=80 bpm)
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Patients with mean heart rates during AF within the RACE criteria (<100 bpm)
Number of subjects: 1091
Study: 15294408

Group type: EXPERIMENTAL
Intervention: Continuous intratracheal insufflation of oxygen (CIO)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation (IPPV)
Number of subjects: 16
Study: 11236242

Group type: EXPERIMENTAL
Intervention: Offspring group (parents with type 2 diabetes)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no family history of diabetes)
Number of subjects: 56
Study: 8910246

Group type: EXPERIMENTAL
Intervention: Adequate physical activity level
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Permanent disability pension
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Excess of major negative life events
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Symptom duration
Number of subjects: 44
Study: 6241559

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (30 micrograms ethinyl estradiol and 150 micrograms levonorgestrel)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Progestin-only preparation (75 micrograms dl-norgestrel)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Non-hormonal controls
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Depot-medroxyprogesterone acetate
Number of subjects: 441
Study: 31713723

Group type: EXPERIMENTAL
Intervention: Ubiquinol 400 mg/day for 3 months
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30067592

Group type: EXPERIMENTAL
Intervention: INT‐CYC
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: INT‐SWI
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: INT‐FOO
Number of subjects: 93

Group type: COMPARATOR
Intervention: CON‐SWI
Number of subjects: 93

Group type: COMPARATOR
Intervention: CON‐FOO
Number of subjects: 93

Group type: COMPARATOR
Intervention: CON‐CYC
Number of subjects: 93
Study: 28319422

Group type: EXPERIMENTAL
Intervention: Low-powered pulsed laser/light
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-powered continuous laser/light
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-powered continuous laser/light
Number of subjects: 40
Study: 25054775

Group type: EXPERIMENTAL
Intervention: 2-month prednisolone treatment
Number of subjects: 255

Group type: COMPARATOR
Intervention: 6-month prednisolone treatment
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 255
Study: 23421353

Group type: EXPERIMENTAL
Intervention: GHB (1, 2, 4, 6, 8, and 10 g/70 kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ethanol (12, 24, 48, 72, 96, and 120 g/70 kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: GHB and Ethanol (highest tolerated doses)
Number of subjects: 14
Study: 21045655

Group type: EXPERIMENTAL
Intervention: 1% PVP-I
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 5% PVP-I
Number of subjects: 200
Study: 18951663

Group type: EXPERIMENTAL
Intervention: PPVC (Smartsite Plus positive bolus valve)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional cap
Number of subjects: 80
Study: 16877376

Group type: EXPERIMENTAL
Intervention: CLD regimen (75 IU FSH for 14 days with 37.5 IU increment)
Number of subjects: 209

Group type: COMPARATOR
Intervention: SQ regimen (half of the FSH dose required for follicular development)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: CLD regimen
Number of subjects: 209

Group type: COMPARATOR
Intervention: SQ regimen
Number of subjects: 209
Study: 12826993

Group type: EXPERIMENTAL
Intervention: SSRI (sertraline)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressant (nortriptyline)
Number of subjects: 22
Study: 10913811

Group type: EXPERIMENTAL
Intervention: Biodegradable polymers with carmustine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8862104

Group type: EXPERIMENTAL
Intervention: Wet nebulizer (WN)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Metered dose inhaler (MDI)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Both WN and MDI
Number of subjects: 95

Group type: COMPARATOR
Intervention: Self-administration of salbutamol by MDI
Number of subjects: 95

Group type: COMPARATOR
Intervention: 400-microgram MDI
Number of subjects: 95

Group type: COMPARATOR
Intervention: MDI therapy with supervision
Number of subjects: 95
Study: 1623994

Group type: EXPERIMENTAL
Intervention: 4.0-cm contraceptive implant
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 2.5-cm contraceptive implant
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both implants
Number of subjects: 48
Study: 6435371

Group type: EXPERIMENTAL
Intervention: Insulin and glibenclamide treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Insulin and placebo
Number of subjects: 20
Study: 30777512

Group type: EXPERIMENTAL
Intervention: Controlled exposure to the target talker's audio recordings for 4 days (Experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural listening environment with manipulated relationships with the talker (Experiment 1)
Number of subjects: 0
Study: 28231835

Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Glibenclamide (2.5 mg bid to a maximal dose of 5 mg bid)
Number of subjects: 64
Study: 26147625

Group type: EXPERIMENTAL
Intervention: Didactic video
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Narrative video
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Narrative infographic
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Didactic infographic
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 194
Study: 24383441

Group type: EXPERIMENTAL
Intervention: Computer tablet-based prenatal psychosocial assessment (e-screening)
Number of subjects: 542

Group type: COMPARATOR
Intervention: Paper-based screening
Number of subjects: 542
Study: 21947373

Group type: EXPERIMENTAL
Intervention: balneotherapy with thermal-mineral water
Number of subjects: 60

Group type: COMPARATOR
Intervention: tap water (control)
Number of subjects: 60
Study: 19265331

Group type: EXPERIMENTAL
Intervention: ReNu MultiPlus
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: OPTIFREE RepleniSH
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Solo‐Care Aqua
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MeniCare Soft
Number of subjects: 25
Study: 17852172

Group type: EXPERIMENTAL
Intervention: MITI coding by trained coders after a 4-month training
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: MITI coding by trained coders
Number of subjects: 7
Study: 15577178

Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) measurements
Number of subjects: 0
Study: 11438404

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9250800

Group type: EXPERIMENTAL
Intervention: Early G-CSF (filgrastim 5 microg/kg/d) from day 4 of IVAP
Number of subjects: 65

Group type: COMPARATOR
Intervention: Late G-CSF (filgrastim 5 microg/kg/d) from day 15 of IVAP
Number of subjects: 65
Study: 8342211

Group type: EXPERIMENTAL
Intervention: Experiential suicide prevention program (7 weekly 2-hour meetings)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 393
Study: 3783203

Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy with cyclophosphamide, methotrexate, 5‐fluorouracil, low‐dose continuous prednisone, and tamoxifen (CMFp + T) for 12 months
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone with prednisone and tamoxifen (p + T) for 1 year
Number of subjects: 463

Group type: COMPARATOR
Intervention: No adjuvant treatment after mastectomy (observation)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy with CMFp + T
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone with p + T
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy (CMFp + T) and observation
Number of subjects: 463
Study: 31283740

Group type: EXPERIMENTAL
Intervention: Superior trunk block
Number of subjects: 126

Group type: COMPARATOR
Intervention: Interscalene block
Number of subjects: 126
Study: 27925651

Group type: EXPERIMENTAL
Intervention: 40 μg/d LNG
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 300, 600, or 1050 μg/d ATZ combined with 40 μg/d LNG
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: ATZ in the dose range investigated
Number of subjects: 66
Study: 26936876

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 568

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 568
Study: 24630348

Group type: EXPERIMENTAL
Intervention: Intramuscular botulinum toxin A (BoNT‐A) injections (n = 23)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham procedure (n = 18)
Number of subjects: 41
Study: 22963982

Group type: EXPERIMENTAL
Intervention: Darapladib
Number of subjects: 323

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Initial presentation with ACS
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 323
Study: 19608026

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg/day
Number of subjects: 307

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day
Number of subjects: 307
Study: 17982194

Group type: EXPERIMENTAL
Intervention: Concurrent treatment with vitamin D(3), VK(2), and EHDP
Number of subjects: 0
Study: 15231925

Group type: EXPERIMENTAL
Intervention: Tymp Aware (physician evaluated tympanometry results)
Number of subjects: 698

Group type: COMPARATOR
Intervention: Tymp Unaware (physician blinded to tympanometry findings)
Number of subjects: 698
Study: 11741360

Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 2457

Group type: COMPARATOR
Intervention: Non-invasive strategy
Number of subjects: 2457
Study: 10514891

Group type: EXPERIMENTAL
Intervention: New mattress overlay
Number of subjects: 413

Group type: COMPARATOR
Intervention: Usual perioperative care
Number of subjects: 413
Study: 7733075

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. x 8 days, Clarithromycin 500 mg b.i.d., CBS 120 mg q.i.d. for 7 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Omeprazole 20 mg b.i.d. x 8 days, Clarithromycin 500 mg b.i.d. (without CBS)
Number of subjects: 61
Study: 2282998

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg t.i.d. and 400 mg nocte for 6 weeks
Number of subjects: 166

Group type: COMPARATOR
Intervention: Pirenzepine 50 mg b.i.d. for 6 weeks
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Cimetidine during follow-up phase
Number of subjects: 166

Group type: COMPARATOR
Intervention: Pirenzepine during follow-up phase
Number of subjects: 166
Study: 7305653

Group type: EXPERIMENTAL
Intervention: Nonoperative management
Number of subjects: 41
Study: 31982317

Group type: EXPERIMENTAL
Intervention: Portomesenteric venous intervention
Number of subjects: 42
Study: 30794665

Group type: EXPERIMENTAL
Intervention: Spousal support (i.e., spouse hand-holding)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-support condition (i.e., alone)
Number of subjects: 80
Study: 28391418

Group type: EXPERIMENTAL
Intervention: Amoxicillin-containing quadruple therapy (esomeprazole 20 mg twice/day, amoxicillin 1000 mg twice/day, levofloxacin 500 mg once/day, bismuth 220 mg twice/day for 14 days)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Cefuroxime-containing quadruple therapy (esomeprazole 20 mg twice/day, cefuroxime 500 mg twice/day, levofloxacin 500 mg once/day, bismuth 220 mg twice/day for 14 days)
Number of subjects: 400
Study: 26362666

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 252

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Included patients
Number of subjects: 252

Group type: COMPARATOR
Intervention: Excluded patients
Number of subjects: 252
Study: 24187860

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion at Baihui (GV 20), Sishencong (EX‐HN 1), Shenmai (BL 62), and Zhaohai (KI 6)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Acupuncture at Shenmen (HT 7), Neiguan (PC 6), and Sanyinjiao (SP 6)
Number of subjects: 120
Study: 22075818

Group type: EXPERIMENTAL
Intervention: Lidocaine + adrenaline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Adrenaline only
Number of subjects: 40
Study: 19656771

Group type: EXPERIMENTAL
Intervention: Dietary energy restriction (DER) - liquid diet, 3,656 kJ/d (864 kcal/d); n = 10
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal eating patterns; n = 9
Number of subjects: 19
Study: 17426677

Group type: EXPERIMENTAL
Intervention: Combination of simvastatin and aspirin
Number of subjects: 263

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 263
Study: 12759560

Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam (TRZ)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.25 mg brotizolam (BRZ)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.125 mg triazolam (TRZ)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo (PLA)
Number of subjects: 10
Study: 11040171

Group type: EXPERIMENTAL
Intervention: Topical amethocaine gel (1.5 g applied to the dorsum of either foot)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (1.5 g applied to the dorsum of either foot)
Number of subjects: 56